Fig 1: CGRP peptide immunogen induces high titers in rats, guinea pigs and monkeys.a Sequence alignment of the 37mer signaling peptide, CGRP. Conserved residues represented by *. Red box indicates the targeting peptide sequence (B cell epitope) of the human αCGRP peptide immunogen, p4796kb, and the rat αCGRP peptide immunogen, p5830kb. Anti-CGRP antibody titers over time in rat (n = 5) (b), guinea pig (n = 3) (c), and NHP (n = 3) (d). Anti-human αCGRP (K35K) (e) and anti-rat αCGRP (K35E) (f) IgG titers in sera collected post-immunization in rats injected with p4796kb or p5380kb (n = 5 per group). g Serum concentrations (μg/mL) of anti-CGRP antibodies. Red arrowheads indicate dosing time points. Individual data points are presented on each graph.
Fig 2: Splenocytes from immunized rats respond to the TH peptide and full peptide immunogen, not to the CGRP peptide.a Representative image from ELISpot plate of IFNγ-secreting splenocytes collected from adjuvant control rats, p4796kb-immunized rats, or p5830kb-immunized rats. Splenocytes were either untreated or stimulated with the Th-peptide, CGRP, the full peptide immunogen, or the positive control Concanavalin A. Empty wells (Blank) are also included. b Quantification of spot count per million cells from the IFNγ ELISpot of splenocytes from rats immunized with p4796kb and p5380kb compared to Adjuvant control. Data are presented as means +/− SEM; n = 5 rats per group. *p < 0.05, **p < 0.01.
Fig 3: Immunization induces antibodies with properties comparable to mAbs.Affinity purified Abs from guinea pigs immunized with p4796kb were compared to the therapeutic mAbs, Galcanezumab and Fremanezumab, in binding potency (a) and in vitro activity assays (b). Inhibition of CGRP-induced cAMP stimulation in SK-N-MC. c Rats immunized with p4796kb and p5380kb were tested for capsaicin-induced dermal blood flow change over time. A two-way ANOVA indicated a significant treatment x time interaction (p < 0.0001), with p5830kb immunization significantly reducing the response to capsaicin (p < 0.0001), however, there was no significant effect of p4796kb immunization. d Area under the curve (AUC) analysis of percent dermal blood flow change; a one-way ANOVA confirmed a significant treatment effect (p < 0.0001); individual data points are presented on each graph and AUC data are also presented as means +/− SEM, n = 6 in the p5830kb group and n = 8 per group for all other treatment groups; *** p = 0.0002; **** p value ≤ 0.0001.
Fig 4: Immunization-induced antibodies are specific to CGRP.Proteome and peptide screens were used to evaluate potential off-target binding of affinity-purified p4796kb antibodies. a Manhattan plot displays results from the HuProt Human Proteome Microarray screen of antibody binding. Colors represent each block from the array, containing approximately 1000 proteins each. Spots represent individual protein intensity score from array. Hits are annotated with protein names. b Manhattan plot from peptide counter screen of 21 putative hits from proteome screen. Overlapping 15mer peptides were synthesized and printed on arrays. Spots represent individual peptide intensity scores from array. Peptide sequences of hits are displayed. Sera from guinea pigs immunized with p4796kb were tested for binding to putative hits from screens (c) and calcitonin family (d) measured by ELISA. Pre-immune sera were used as controls. Data are presented as means +/− SEM; n = 3. ***p < 0.0001.
Fig 5: Immunization induces an IgG1 enriched response against CGRP.Anti-human αCGRP IgG (a) and IgM (b) titers in rats following immunization with p4796kb formulated in Adju-Phos® (AP) or ISA-51VG (ISA) over time. c anti-CGRP IgG isotype titers from the terminal bleed of rats immunized with p4796kb formulated in Adju-Phos®. d Endpoint anti-CGRP IgG isotyping from monkeys injected with three doses three weeks apart of p4796kb formulated in Adju-Phos®. Red arrows indicate dosing time points. Individual data points are presented on each graph, except in (b) where data are presented as means +/− SEM. For rat study n = 5 per group. For NHP study n = 3 per group.
Supplier Page from Abcam for Recombinant Human Calcitonin protein